ArticleCancer immunology, immunotherapy : CII2011

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.

Joseph M Tuscano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.